Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lucatumumab
HCD122 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| HCD122 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HCD122 | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of follicular lymphoma, according to the Revised European American Lymphoma/World Health Organization \[REAL/WHO\] classification * Documented CD40+ follicular lymphoma * Measurable lesion * Refractory to rituximab * Prior treatment with at least 1 chemothe...
HCD122 is an investigational drug being studied for use in multiple myeloma, non-Hodgkin's lymphoma, and follicular lymphoma. It is in Phase 1 clinical development for these oncology indications.
HCD122 is a monoclonal antibody that targets CD40, as indicated by its study in CD40+ rituximab-refractory follicular lymphoma. It is being developed as a potential treatment for certain B-cell malignancies.
HCD122 is being developed by Novartis AG, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS.
HCD122 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed for multiple myeloma, non-Hodgkin's lymphoma, and follicular lymphoma.
HCD122 has been studied in three completed Phase 1 trials: NCT00231166 in multiple myeloma, NCT00670592 in non-Hodgkin's or Hodgkin's lymphoma, and NCT01275209 in follicular lymphoma. These trials were open-label and uncontrolled.
Yes, HCD122 is also known as lucatumumab. The clinical trial NCT01275209 refers to HCD122 (Lucatumumab) in its title, confirming that both names refer to the same investigational drug.